{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to date of death or date last known alive.","groups":[{"description":"Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm E (Phase II: Rituximab, Bortezomib, Dexamethasone)"},{"description":"Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm E. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)"}],"populationDescription":"No patients were enrolled in the phase II part of this study.","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months if <2 years of study entry, every 6 months if 2-5 years of study entry, and annually if 6-10 years","title":"Phase II: Overall Survival","type":"SECONDARY"}